C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 99 filers reported holding C4 THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.06 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $3,476 | -77.2% | 1,107 | -57.1% | 0.00% | -100.0% |
| Q4 2022 | $15,240 | -32.7% | 2,583 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $22,653 | +16.3% | 2,583 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $19,476 | -68.9% | 2,583 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $62,664 | -81.2% | 2,583 | -75.1% | 0.00% | -60.0% |
| Q4 2021 | $334,075 | -27.9% | 10,375 | 0.0% | 0.01% | -28.6% |
| Q3 2021 | $463,555 | +20.1% | 10,375 | +1.7% | 0.01% | +40.0% |
| Q2 2021 | $385,892 | +179.2% | 10,198 | +172.9% | 0.01% | +150.0% |
| Q1 2021 | $138,232 | +11.7% | 3,737 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $123,807 | – | 3,737 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |